URAC Rare Disease Pharmacy Center of Excellence Consulting — Integral Healthcare Solutions
Last updated: April 2026
IHS guides specialty pharmacies through every phase of URAC Rare Disease Pharmacy Center of Excellence Certification — from eligibility assessment and standards gap analysis through documentation preparation, mock review, and final submission. Thomas G. Goddard, JD, PhD, former Chief Operating Officer and General Counsel of URAC, leads engagements with firsthand knowledge of how URAC evaluates these standards from the inside.
What Is URAC Rare Disease Pharmacy Center of Excellence Certification?
URAC Rare Disease Pharmacy Center of Excellence Certification is the quality designation that distinguishes specialty pharmacies with advanced capabilities in serving patients living with rare and orphan diseases. It is one of only two URAC "Certification" programs in the pharmacy space and functions as a specialized layer built on top of URAC Specialty Pharmacy Accreditation — adding five additional standards that go beyond the baseline specialty pharmacy requirements.
The program was developed with input from NORD — the National Organization for Rare Disorders — and reflects current best practices for patient management, care coordination, and outcomes improvement in a population where the margin for error is extraordinarily low. Only approximately 23 specialty pharmacies nationwide hold this designation.
The Five Additional Standards
Rare Disease Certification adds five standards to an organization's existing specialty pharmacy accreditation, requiring demonstrated performance across:
- Rare disease-specific clinical assessment — individualized assessments integrated into patient management for each rare or orphan condition dispensed
- Education and support programs — structured disease-specific education for patients, caregivers, providers, and payers, not generic specialty pharmacy education
- Multidisciplinary team collaboration — documented coordination among pharmacists, care coordinators, clinical specialists, and treating providers across the care continuum
- Data collection and analytics — population-level tracking of clinical outcomes, adherence, and quality indicators for the rare disease patient population
- Continuous quality improvement — a structured CQI program specifically evaluated against rare disease performance measures and outcomes
Who Needs URAC Rare Disease Pharmacy Center of Excellence Certification?
URAC Rare Disease Pharmacy Center of Excellence Certification is pursued by specialty pharmacies that dispense — or intend to dispense — rare and orphan medications and need to demonstrate to manufacturers, payers, and referral sources that their operations meet an elite standard of rare disease care.
- Specialty pharmacies seeking limited-distribution drug access — manufacturers of rare and orphan drugs commonly restrict distribution to pharmacies that can demonstrate the enhanced patient services their products require; this certification is the recognized proof point
- Specialty pharmacies expanding into rare disease therapeutic categories — organizations building out rare disease service lines (hemophilia, lysosomal storage disorders, neuromuscular diseases, hereditary angioedema, enzyme replacement therapies) that need credentialing to match their clinical ambitions
- Integrated delivery networks and health system pharmacies — hospital-based and health system specialty pharmacies competing for rare disease patient volumes against large national operators
- PBM-owned specialty pharmacies — entities competing for manufacturer preferred distribution agreements where quality differentiation determines selection
- Pharmacies holding URAC Specialty Pharmacy Accreditation — organizations already accredited that want to elevate their competitive position and expand drug access without undergoing a separate full accreditation cycle
The rare disease pharmaceutical market represents one of the highest-growth segments in specialty pharmacy. Orphan drug sales exceed $200 billion globally and are growing faster than any other drug category. Rare disease patient populations are small, complex, and require a level of clinical coordination that most general specialty pharmacies are not equipped to document at the standard URAC requires.
The URAC Rare Disease Pharmacy Center of Excellence Certification Process
Rare Disease Certification is pursued as a concurrent or follow-on engagement to URAC Specialty Pharmacy Accreditation. The five additional standards require operational evidence — not policy alone — which means your organization must be actively serving rare disease patients with documented processes before the survey date. Here is how IHS structures the engagement.
Phase 1: Eligibility Confirmation and Standards Gap Analysis
IHS confirms your organization's eligibility — active dispensing of at least one rare or orphan drug, current or concurrent pursuit of URAC Specialty Pharmacy Accreditation — and conducts a standards gap analysis across all five Rare Disease certification standards. This phase identifies what your organization already has in place versus what must be built, and produces a remediation roadmap with timelines aligned to your accreditation survey schedule.
Many pharmacies underestimate the operational specificity required. General specialty pharmacy patient management processes do not satisfy the Rare Disease standards. IHS identifies these gaps early, before your team invests documentation effort in processes that will not survive URAC review.
Phase 2: Policy and Program Development
IHS provides templates and guidance for all five Rare Disease standards: rare disease clinical assessment protocols tailored to your specific drug portfolio, disease-specific education program documentation for each condition dispensed, multidisciplinary team structure and collaboration documentation, data collection and analytics frameworks for your rare disease patient population, and CQI program documentation with rare disease-specific performance measures. Your team adapts these frameworks to your operational context and begins generating audit-ready evidence.
Phase 3: Mock Review and Evidence Audit
IHS conducts a mock review of your Rare Disease documentation — auditing patient files, education program records, multidisciplinary team documentation, and CQI reports against the five standards. Deficiencies identified here are corrected before URAC surveyors see them. This is where most preventable failures are caught: incomplete disease-specific assessments, generic education materials that do not satisfy the disease-specificity requirement, or CQI programs that track general metrics rather than rare disease outcomes.
Phase 4: Application Submission and Survey Support
IHS supports preparation of the formal application, coordinates submission timing with your Specialty Pharmacy Accreditation cycle where applicable, and provides direct support during the URAC review process. If Requests for Information (RFIs) are issued, IHS supports response drafting and evidence assembly within URAC's response windows.
What URAC Evaluates
URAC surveyors evaluate the Rare Disease Certification standards with the same rigor applied to the full Specialty Pharmacy Accreditation — through file review, policy review, and documentation audit. Key evaluation areas include:
- Disease-specific clinical assessments integrated into patient management records — not generic templates applied across all specialty conditions
- Education program content tailored to specific rare diseases, not general specialty pharmacy patient education
- Documentation of actual multidisciplinary team interactions — meeting records, care plan coordination notes, provider communication logs
- Analytics outputs demonstrating population-level tracking of rare disease patient outcomes
- CQI program reports with rare disease-specific performance measures and evidence of improvement activity
Common Rare Disease Certification Deficiencies
The most frequent deficiencies in URAC Rare Disease certification reviews follow predictable patterns. IHS has identified these failure modes and structures preparation to prevent them.
1. Generic Patient Management Applied to Rare Disease Patients
The standard requires: Clinical assessments and patient management protocols specific to each rare or orphan condition dispensed.
How pharmacies fail: Organizations apply their standard specialty pharmacy patient management templates to rare disease patients without disease-specific modifications. URAC surveyors identify this immediately — a hemophilia patient management protocol that looks identical to a rheumatoid arthritis protocol fails the specificity requirement.
How IHS prevents it: Our gap analysis evaluates your patient management documentation against each rare disease condition in your drug portfolio. We provide disease-specific assessment frameworks and flag templated approaches before they reach the survey.
2. Non-Disease-Specific Education Programs
The standard requires: Education and support programs tailored to the specific rare disease, not general specialty pharmacy patient education.
How pharmacies fail: Organizations provide generic specialty pharmacy education materials — medication adherence reminders, refill coordination protocols — and present them as rare disease education programs. The standard requires condition-specific content addressing the unique clinical, psychosocial, and caregiver dimensions of the patient's disease.
How IHS prevents it: We review your education program content against each disease in your portfolio and provide frameworks for building disease-specific programs that meet URAC's specificity standard.
3. Undocumented Multidisciplinary Collaboration
The standard requires: Documented evidence of actual multidisciplinary team collaboration — not just an organizational chart showing that the team exists.
How pharmacies fail: Organizations have multidisciplinary teams in practice but lack documentation of collaboration events, care plan inputs, and provider communication. URAC requires evidence, not attestation.
How IHS prevents it: We provide documentation frameworks for capturing multidisciplinary team interactions in patient records and structure your care coordination processes to generate audit-ready evidence from day one.
4. Analytics Gaps in Rare Disease Population Tracking
The standard requires: Data collection and analytics demonstrating population-level tracking of rare disease patient outcomes.
How pharmacies fail: Organizations track general specialty pharmacy performance measures — refill rates, call response times — without building rare disease-specific analytics. URAC expects evidence that your organization is monitoring outcomes specific to the rare disease population, not general operational metrics.
How IHS prevents it: Our Phase 2 work includes analytics framework development with rare disease-appropriate performance measures. We identify what your current systems can capture and where supplemental tracking is needed before the survey date.
5. CQI Programs That Do Not Reach Rare Disease Outcomes
The standard requires: A continuous quality improvement program evaluated against rare disease performance measures.
How pharmacies fail: Organizations submit their standard specialty pharmacy CQI program — which addresses general operational quality — without adaptation to rare disease outcomes. The Rare Disease standard requires CQI activity traceable to the specific patient population.
How IHS prevents it: We review your CQI program design against the Rare Disease standard and provide templates for incorporating rare disease-specific measures into your existing quality infrastructure.
Why IHS for URAC Rare Disease Pharmacy Certification
Thomas G. Goddard, JD, PhD, served as the Chief Operating Officer and General Counsel of URAC — the organization that wrote and administers the Rare Disease Pharmacy Center of Excellence standards. That experience is not a marketing credential. It means IHS understands how URAC evaluates these standards from the inside: what surveyors look for, where organizations consistently fall short, and what documentation actually satisfies each requirement versus what merely addresses it on paper.
What Sets IHS Apart
- Former URAC COO and General Counsel — Thomas G. Goddard, JD, PhD led URAC operations and legal strategy; IHS consults from inside knowledge of URAC program development and standards administration
- Specialty pharmacy accreditation integration — IHS manages the Specialty Pharmacy Accreditation and Rare Disease Certification as a coordinated engagement, eliminating redundant documentation effort and aligning survey timelines
- Drug portfolio-specific preparation — IHS structures preparation around your actual rare disease drug portfolio, not a generic template applicable to any condition
- Evidence-first approach — IHS distinguishes between what URAC requires on paper and what URAC actually evaluates in the file review; preparation targets the audit, not just the checklist
- RFI support through resolution — if URAC issues Requests for Information during review, IHS provides direct response support through the final decision
Adjacent Services
IHS provides consulting across the full URAC pharmacy program portfolio. Organizations pursuing Rare Disease Certification typically hold or are pursuing URAC Specialty Pharmacy Accreditation — IHS coordinates both engagements. For pharmacies evaluating the full landscape of specialty pharmacy quality credentials, see our specialty pharmacy accreditation comparison.
Schedule a Free Discovery Session
IHS offers a complimentary discovery session to evaluate your organization's eligibility for URAC Rare Disease Pharmacy Center of Excellence Certification, assess your current accreditation posture, and identify the gap between where your organization is today and what the certification requires. Bring your drug portfolio, your current accreditation status, and your timeline — we will tell you exactly what the path looks like.